Announced Exclusive Licensing Agreement with Viatris for Sotagliflozin in all Markets Outside of the U.S. and Europe Completed ZYNQUISTA FDA Advisory Committee Meeting; PDUFA Goal Date December 20, 20 ...
GLP-1, SGLT2 medications may lower risk of future MI and repeat stroke among stroke survivors: Study
GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or ...
HealthDay on MSN13h
AHA: GLP-1 RA, SGLT-2i Use Can Lower Risk for MI, Recurrent Stroke in Stroke SurvivorsFor patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor ...
Hosted on MSN14h
SGLT-2 Inhibitors Beneficial for Patients With NephrolithiasisTUESDAY, Nov. 12, 2024 (HealthDay News) -- For patients with nephrolithiasis, sodium-glucose cotransporter-2 (SGLT-2) ...
THE WOODLANDS, Texas, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended September 30, 2024 and provided an ...
The Prescription Drug User Fee Act date refers to the deadline set by the FDA for reviewing a NDA or Biologics License Application.
Stroke survivors who took GLP-1 or SGLT2 medications had a 74% lower risk of death, according to a preliminary study being presented at the American Heart Association's annual Scientific Sessions, set ...
"Canagliflozin was linked to enhanced iron utilization and elevated hemoglobin levels in adults with type 2 diabetes and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback